Antithrombotic therapy in patients with atrialfibrillation after percutaneous coronary stenting:between scylla and charybdis
Authors:
Company: Cardiology Chair of Moscow State University of Medicine and Dentistry named after A.I. Evdokimov of Ministry of Health of the Russian Federation; Delegatskaya ulitsa, 20/1, Moscow, 127473, Russian Federation
For correspondence: Sign in or register.
DOI:
For citation: Shpektor A.V. Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary stenting: between Scylla and Charybdis. Kreativnaya kardiologiya (Creative Cardiology, Russian journal). 2017; 11 (1): 5–7 (in Russ.). DOI: 10.15275/kreatkard.2017.01.01
Received / Accepted: March 07, 2017 / March 15, 2017
References
Kirchhof P., Benussi S., Kotecha D. et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016; 37 (38): 2893–962.
Dewilde W.J., Oirbans T., Verheuqt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an openlabel, randomised, controlled trial. Lancet. 2013; 381 (9872): 1107–15.
Gibson C.M., Mehran R., Bode C. et al. An open label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am. Heart J. 2015; 169 (4): 472–8.
Gibson C.M., Pinto D.S., Chi G. et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a doseadjusted oral vitamin k antagonist treatment strategy. Circulation. 2017; 135 (4): 323–33.
